Extension of Composite Tissue Allograft Survival Across Major Histocompatibility Barrier Under Short Course of Anti-Lymphocyte Serum and Cyclosporine A Therapy

Kagan Ozer; Raffi Gurunluoglu; Maciej Zielinski; Dariusz Izycki; Murat Unsal; Maria Siemionow

doi:10.1055/s-2003-40581

Journal of Reconstructive Microsurgery, Table of Contents

J Reconstr Microsurg 2003; 19(4): 249-256
DOI: 10.1055/s-2003-40581

Extension of Composite Tissue Allograft Survival Across Major Histocompatibility Barrier Under Short Course of Anti-Lymphocyte Serum and Cyclosporine A Therapy

Kagan Ozer, Raffi Gurunluoglu, Maciej Zielinski, Dariusz Izycki, Murat Unsal, Maria Siemionow

Department of Plastic Surgery, The Cleveland Clinic Foundation, Cleveland, OH

Abstract

ABSTRACT

In this study, the authors investigated the effects of combined use of cyclosporine A (CsA) and anti-lymphocyte serum (ALS) on the survival of rat hindlimb allografts across a fully allogeneic major histocompatibility complex (MHC) barrier between Brown-Norway rats (BN, RT1ⁿ) and Lewis rats (LEW, RT1^l). Thirty transplantations were performed in five groups of six rats each: Group 1 was the isograft control; Group 2 was the allograft control; Group 3 received ALS, Group 4 received CsA, and Group 5 received CsA and ALS. Treatment was started 2 hr before surgery and was then given for 21 days. Donor-derived chimerism was monitored by FACS analysis. Survival time was calculated as the number of post-transplant days until the first signs of rejection. The allografts in Group 2, Group 3, and Group 4 survived a mean of 5, 6, and 33 days, respectively. The longest mean survival time-51 days-was noted in Group 5 (p<0.05). Donor- derived chimerism peaked at 17 percent and fell to 0 percent at the time of rejection. A combined protocol of ALS/CsA extended survival of rat hindlimb allografts across a fully allogeneic MHC barrier.

KEYWORDS

Anti-lymphocyte serum - composite tissue allograft - cyclosporine - rat - hindlimb.

Full Text

References

REFERENCES

1 Jones J W, Gruber S A, Barker J H, Breidenbach W C. Successful hand transplantation. One-year follow-up. Louisville Hand Transplant Team. N Engl J Med.. 2000; Aug 17; 343 468-473
2 Jones T R, Humphrey P A, Brennan D C. Transplantation of vascularized allogeneic skeletal muscle for scalp reconstruction in a renal transplant patient. Transplant Proc . 1998; 30 2746-2753
3 Lorenz R R, Fritz M A, Strome M. Special feature: current state of laryngeal transplantation. Curr Opin Otolaryn Head Neck Surg . 2001; 9 381-386
4 Foster R P, Fan L, Niepp M. et al . Donor specific tolerance induction in composite tissue allografts. Am J Surg . 1998; 176 418-421
5 Sharabi Y, Sachs D H. Mixed chimerism and permanent specific transplantation tolerance induced by nonlethal preparative regimen. J Exp Med . 1989; 169 493-502
6 Qin S, Cobbold S, Benjamin R, Waldmann H. Induction of classical transplantation tolerance in the adult. J Exp Med . 1989; 169 779-794
7 Colson Y L, Wren S M, Schuchert M J. et al . A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. J Immunol . 1995; 155 4179-4188
8 Kawai T, Cosimi A B, Colvin R B. et al . Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation . 1995; 59 256-262
9 Ozer K, Oke R, Prajapati R, Siemionow M. Combined use of anti-lymphocyte serum and cyclosporine A induces tolerance in rat hind limb allografts. Paper presented at the 46th Annual Meeting, Plastic Surgery Research Council, Milwaukee, WI, June, 2001
10 White D JG, Plumb A M, Pawelec G. et al . Cyclosporine A: an immunosuppressive agent preferentially active against proliferating T cells. Transplantation . 1979; 27 55-58
11 Brent L. Immunoregulation: the search for the holy grail. In: Brent L, ed. History of Transplantation Immunology San Diego: Academic Press, 1997: 230-304
12 Press B HJ, Sibley R K, Shons A R. Limb allotransplantation in the rat: extended survival and return of nerve function with continuous cyclosporin/prednisone immunosuppression. Ann Plast Surg . 1986; 16 313-321
13 Hewitt C W, Black K S, Fraser L A. et al . Composite tissue (limb) allografts in rats. I: Dose-dependent increase in survival with cyclosporine. Transplantation . 1985; 39 360-364
14 Black K S, Hewitt C W, Fraser L A. et al . Composite tissue (limb) allografts in rats. II: Indefinite survival using low-dose cyclosporine. Transplantation . 1985; 39 365-368
15 Press B HJ, Sibley R K, Shons A R. Limb allotransplantation in the rat: extended survival and return of nerve function with continuous cyclosporin/prednisone immunosuppression. Ann Plast Surg . 1986; 16 313-321
16 Black K S, Hewitt C W, Hwang J S. et al . Dose response of cyclosporine-treated composite tissue allografts in a strong histoincompatible rat model. Transplant Proc . 1988; 20 266-268
17 Hotokebuchi T, Arai K, Takagishi K. et al . Limb allografts in rats immunosuppressed with cyclosporine: as a whole joint allograft. Plast Reconstr Surg . 1989; 83 1027-1036
18 Doi K, DeSantis G, Singer D I. et al . The effect of immunosuppression on vascularized allografts. J Bone Joint Surg . 1989; 71B 576-582
19 Arai K, Hotokebuchi T, Miyahara H. et al . Prolonged limb allograft survival with short-term treatment with FK-506 in rats. Transplant Proc . 1989; 21 3191-3193
20 Fealy M J, Umansky W S, Bickel K D. et al . Efficacy of rapamycin and FK506 in prolonging rat hind limb allograft survival. Ann Surg . 1994; 219 88-93
21 Muramatsu K, Doi K, Shigetomi M. et al . A new immunosuppressant, FTY 720, prolongs limb allograft survival in rats. Ann Plast Surg . 1998; 40 160
22 Inceoglu S, Siemionow M, Chick L. et al . The effect of combined immunosuppression with systemic low-dose cyclosporin and topical fluocinolone acetonide on the survival of rat hind limb allografts. Ann Plast Surg . 1994; 33 57-65
23 Buttemeyer F, Jones N F, Min Z, Rao U. Rejection of the component tissues of limb allografts in rats immunosuppressed with FK-506 and cyclosporine. Plast Reconstr Surg . 1996; 97 139-148
24 Hewitt C W, Black K S, Fraser L A. et al . Cyclosporine A is superior to prior donor-specific blood transfusion for the extensive prolongation of rat limb allograft survival. Transplant Proc . 1983; 15 514-517
25 Salvatierra O, Vincenti F, Amend W. et al . Deliberate donor-specific blood transfusions prior to living related renal transplantation. A new approach. Ann Surg . 1980; 192 543-552
26 Barber W H, Mankin J A, Laskow D A. et al . Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation . 1991; 51 70-75
27 Wolden S L, Tate D J, Hunt S A. et al . Long-term results of total lymphoid irradiation in the treatment of cardiac allograft rejection. Int J Radiat Oncol Biol Phys . 1997; 39 953-960
28 Zwan A V, Besseling A C, Waal L P, Boog C JP. Specific tolerance induction and transplantation: a single-day protocol. Blood . 1997; 89 2596-2601
29 El Badri S N, Good R A. Induction of immunological tolerance in full major and multiminor histocompatibility-disparate mice using a mixed bone marrow transplantation. Proc Soc Exp Med . 1994; 205 67-74
30 Fontes P, Rao A S, Demetris A J. et al . Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet . 1994; 344 151-155
31 Rao A S, Fontes P, Zeevi A. et al . Augmentation of chimerism in whole organ recipients by simultaneous infusion of donor bone marrow cells. Transplant Proc . 1995; 27 210-212
32 Murase N, Demetris A J, Fujisaki S. et al . Bone marrow augmentation for heart, liver, and small bowel transplantation: prolongation of graft survival and incidence of graft-versus-host disease. Transplant Proc . 1995; 27 174-175
33 Hanaway M J, Geissler E K, Wang J. et al . Immunosuppressive effects of an HLA class I-derived peptide in a rat cardiac allograft model. Transplantation . 1996; 61 1222-1228
34 Ishikura H, Natori T, Aizawa M. Host-origin dendritic cells in acutely rejected rat renal allografts. Transplant Proc . 1985; 17 875-879
35 Katz S M, Carmer D V, Kunz H W. et al . Effect of major histocompatibility complex genetic disparities on cardiac and skin graft rejection in the rat. Transplantation . 1983; 36 463-464
36 Terasaki P I, Cho Y, Takemoto S. et al . Twenty year follow-up on the effect of HLA matching on kidney transplant survival and prediction of future twenty-year survival. Transplant Proc . 1996; 28 1144-1145
37 Tsuchimoto S, Mizuno K, Matsuno Y. et al . The effect of RT1 subregion differences on liver allograft survival in the rat. Transplantation . 1985; 40 218-220
38 Iwasaki N, Gohda T, Itoga H. et al . Effects of major histocompatibility complex matching in graft survival in allogeneic rat hind limb transplantation. J Hand Surg . 2001; 26A 540-545
39 Gill III J T, Kunz H W, Misra D N. et al . The major histocompatibility complex of the rat. Transplantation . 1987; 43 773-785